We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Apellis Pharmaceuticals and Beam Therapeutics have forged a five-year research partnership that will apply the latter's base-editing platform toward discovering new treatments for complement-driven diseases, the companies announced Wednesday.